Development of a Nanoliposomal Formulation of Erlotinib for Lung Cancer and in vitro/In vivo Antitumoral Evaluation
- Type
- Retraction
- Notice date
- 11/18/2022 0:00
- Journal
- Drug Design, Development and Therapy
- Publisher
- Taylor and Francis - Dove Press
- Notice DOI
- 10.2147/dddt.s398024
- Original paper DOI
- 10.2147/dddt.s146925